Key result
SLC12A3 gene variant is linked to a ~9-fold increased risk of hydrochlorothiazide-induced hyponatremia.
Why the study?
Do variants in the SLC12A3 gene increase the risk of hydrochlorothiazide-associated hyponatremia in hypertensive patients?
Case-Control (n=95)
No
Do variants in the SLC12A3 gene increase the risk of hydrochlorothiazide-associated hyponatremia in hypertensive patients?
Answers are grounded in this paper and cite their sources.
Genetic variants in the SLC12A3 gene, particularly c.282+492G>A, are significantly associated with an increased risk of hydrochlorothiazide-induced hyponatremia in hypertensive patients.
Objective Hyponatremia is one of the most common electrolyte disorders in clinical practice and is frequently observed following thiazide use. Advanced age and female gender are implicated in the etiology of hydrochlorothiazide (HCTZ)-associated hyponatremia. There has also recently been mention of a genetic disposition. This study evaluated the genetic component, and particularly the clinical significance, of variants in the SLC12A3 gene in the development of hyponatremia in hypertensive patients using HCTZ-group diuretics.Method Ninety-five patients presenting to the Tekirdağ Namık Kemal University nephrology clinic and receiving antihypertensive therapy including HCTZ for at least one month were examined. Peripheral blood specimens were collected from hyponatremic (n = 62) and non-hyponatremic (n = 33) individuals. Variants in the SLC12A3 gene were analyzed using next generation sequencing and were compared with the clinical data.Results A total of 947 variants were detected in the SLC12A3 gene, the majority of which were classified as of uncertain significance. Hyponatremia was determined at a higher rate in patients with c.506-276A>G (75.00%), c.282+492G>A (85.70%), c.282+499G>C (87.00%), c.282+495G>A (85.00%), and c.505+375G>A (92.30%) variants in particular. The risk of hyponatremia development increased 9.2-fold in the presence of the c.282+492G>A variant (OR = 9.243; 95% CI: 2.259–37.818; p = 0.002).Conclusion In conclusion, we think that HCTZ-associated hyponatremia cannot be predicted by clinical and biochemical parameters alone, and that genetic factors should also be considered. Further multi-center prospective studies involving larger populations will clarify the clinical significance of variants in SLC12A3 and other genes and will make a significant contribution to individualized therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Ozkan et al. (2026) conducted a case-control in Hydrochlorothiazide-associated hyponatremia (n=95). SLC12A3 gene variants (e.g., c.282+492G>A) vs. Absence of the variant was evaluated on Development of hyponatremia (OR 9.243, 95% CI 2.259-37.818, p=0.002). The c.282+492G>A variant in the SLC12A3 gene was associated with a increased risk of hydrochlorothiazide-associated hyponatremia.
Synapse has enriched 10 related papers. Consider them for comparative context: